$Butterfly Network(BFLY.US) is finally starting to get some attention again.

What makes this one interesting to me is that Butterfly recently received FDA clearance for an AI-powered ultrasound tool for pregnancy assessment, which adds another layer to its portable ultrasound story. The company says the tool can estimate gestational age in under two minutes and it was trained on more than 21 million ultrasound images.

There’s also been some improvement in the business itself. In Butterfly’s latest reported quarter, revenue rose 41% year over year to a record $31.5 million, the company generated positive net cash flow of $6.3 million, and it reported its lowest annual cash usage in company history.

For me, that makes BFLY more interesting than a pure hype move. It still looks like a volatile medtech name, but there are actual product and execution developments behind the story.